Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALNY OTCMKTS:OPHLF NASDAQ:RPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$300.51+0.7%$311.62$284.19▼$495.55$39.85B0.311.07 million shs650,230 shsOPHLFOno Pharmaceutical$14.55$14.41$9.20▼$18.67$6.84B0.331 shsN/ARPRXRoyalty Pharma$53.55+0.9%$48.87$32.15▼$53.59$30.55B0.43.65 million shs2.84 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals+0.68%+2.41%-2.57%-10.61%+2.71%OPHLFOno Pharmaceutical0.00%0.00%0.00%-10.46%+40.20%RPRXRoyalty Pharma+0.92%+0.28%+8.23%+18.68%+63.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALNYAlnylam Pharmaceuticals$300.51+0.7%$311.62$284.19▼$495.55$39.85B0.311.07 million shs650,230 shsOPHLFOno Pharmaceutical$14.55$14.41$9.20▼$18.67$6.84B0.331 shsN/ARPRXRoyalty Pharma$53.55+0.9%$48.87$32.15▼$53.59$30.55B0.43.65 million shs2.84 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALNYAlnylam Pharmaceuticals+0.68%+2.41%-2.57%-10.61%+2.71%OPHLFOno Pharmaceutical0.00%0.00%0.00%-10.46%+40.20%RPRXRoyalty Pharma+0.92%+0.28%+8.23%+18.68%+63.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALNYAlnylam Pharmaceuticals 2.85Moderate Buy$463.1354.12% UpsideOPHLFOno Pharmaceutical 2.00HoldN/AN/ARPRXRoyalty Pharma 3.00Buy$53.710.31% UpsideCurrent Analyst Ratings BreakdownLatest OPHLF, ALNY, and RPRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026ALNYAlnylam Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$380.005/18/2026ALNYAlnylam Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/15/2026RPRXRoyalty Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/7/2026RPRXRoyalty Pharma CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $66.005/7/2026RPRXRoyalty Pharma JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$50.00 ➝ $58.005/5/2026ALNYAlnylam Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$510.005/4/2026ALNYAlnylam Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/1/2026RPRXRoyalty Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/1/2026ALNYAlnylam Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$450.00 ➝ $445.005/1/2026ALNYAlnylam Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$376.00 ➝ $377.004/21/2026RPRXRoyalty Pharma UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$51.00 ➝ $57.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALNYAlnylam Pharmaceuticals$3.71B10.80$2.82 per share106.75$8.05 per share37.33OPHLFOno Pharmaceutical$3.20B2.14$1.08 per share13.50$11.07 per share1.31RPRXRoyalty Pharma$2.38B12.97$4.82 per share11.11$17.26 per share3.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALNYAlnylam Pharmaceuticals$313.75M$3.6682.1129.26N/A11.72%85.76%10.32%7/30/2026 (Estimated)OPHLFOno Pharmaceutical$330.31M$0.8916.3515.65N/A12.29%7.76%5.91%8/3/2026 (Estimated)RPRXRoyalty Pharma$770.95M$1.4736.439.721.4633.88%29.25%14.71%8/5/2026 (Estimated)Latest OPHLF, ALNY, and RPRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026RPRXRoyalty Pharma$1.22$1.30+$0.08$0.67$881.69 million$631.00 million4/30/2026Q1 2026ALNYAlnylam Pharmaceuticals$0.8720$1.99+$1.1180$1.51$1.12 billion$1.17 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALNYAlnylam PharmaceuticalsN/AN/AN/AN/AN/AOPHLFOno PharmaceuticalN/AN/AN/AN/AN/ARPRXRoyalty Pharma$0.941.76%+24.01%63.95%5 YearsLatest OPHLF, ALNY, and RPRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/17/2026RPRXRoyalty Pharmaquarterly$0.23501.78%5/15/20265/15/20266/10/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALNYAlnylam Pharmaceuticals0.943.133.06OPHLFOno Pharmaceutical0.103.022.56RPRXRoyalty Pharma0.862.662.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALNYAlnylam Pharmaceuticals92.97%OPHLFOno PharmaceuticalN/ARPRXRoyalty Pharma54.35%Insider OwnershipCompanyInsider OwnershipALNYAlnylam Pharmaceuticals0.86%OPHLFOno PharmaceuticalN/ARPRXRoyalty Pharma18.84%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALNYAlnylam Pharmaceuticals2,770133.51 million132.37 millionOptionableOPHLFOno Pharmaceutical4,287469.91 millionN/ANot OptionableRPRXRoyalty Pharma80575.83 million467.35 millionOptionableOPHLF, ALNY, and RPRX HeadlinesRecent News About These CompaniesInsider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 13,684 Shares of Stock3 hours ago | marketbeat.comRoyalty Pharma (NASDAQ:RPRX) Hits New 12-Month High - What's Next?May 21 at 5:35 PM | marketbeat.comFideuram Intesa Sanpaolo Private Banking S.P.A. Invests $4.92 Million in Royalty Pharma PLC $RPRXMay 21 at 5:33 AM | marketbeat.comThrivent Financial for Lutherans Acquires 22,015 Shares of Royalty Pharma PLC $RPRXMay 20 at 6:48 AM | marketbeat.comMarathon Asset Management Ltd Has $15 Million Stake in Royalty Pharma PLC $RPRXMay 20 at 5:59 AM | marketbeat.com49,855 Shares in Royalty Pharma PLC $RPRX Acquired by Partners Group Holding AGMay 20 at 5:58 AM | marketbeat.comRoyalty Pharma PLC $RPRX Shares Acquired by Cullen Frost Bankers Inc.May 20 at 4:12 AM | marketbeat.comRoyalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 TranscriptMay 19 at 1:03 PM | seekingalpha.comRoyalty Pharma (RPRX) Benefits from Biotech Funding Gap with Rising Returns and Market DominanceMay 18, 2026 | insidermonkey.comRoyalty Pharma (NASDAQ:RPRX) Director Sells $161,385.00 in StockMay 18, 2026 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) EVP Sells $726,073.04 in StockMay 18, 2026 | americanbankingnews.comQsemble Capital Management LP Invests $2.88 Million in Royalty Pharma PLC $RPRXMay 17, 2026 | marketbeat.comCommerzbank Aktiengesellschaft FI Invests $982,000 in Royalty Pharma PLC $RPRXMay 17, 2026 | marketbeat.comRoyalty Pharma PLC (NASDAQ:RPRX) Given Consensus Rating of "Buy" by AnalystsMay 16, 2026 | marketbeat.comRoyalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst QuestionsMay 16, 2026 | finance.yahoo.comGregory Norden Sells 3,045 Shares of Royalty Pharma (NASDAQ:RPRX) StockMay 16, 2026 | insidertrades.comRoyalty Pharma: Strong Execution, Expanding Pipeline And More Firepower AheadMay 16, 2026 | seekingalpha.comRoyalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comIncome Investors Should Know That Royalty Pharma plc (NASDAQ:RPRX) Goes Ex-Dividend SoonMay 11, 2026 | finance.yahoo.comRoyalty Pharma (RPRX) Gets a Buy from TD CowenMay 11, 2026 | theglobeandmail.comHosking Partners LLP Purchases 155,450 Shares of Royalty Pharma PLC $RPRXMay 11, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOPHLF, ALNY, and RPRX Company DescriptionsAlnylam Pharmaceuticals NASDAQ:ALNY$300.51 +2.03 (+0.68%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$302.55 +2.04 (+0.68%) As of 05/21/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Ono Pharmaceutical OTCMKTS:OPHLF$14.55 0.00 (0.00%) As of 05/18/2026Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.Royalty Pharma NASDAQ:RPRX$53.55 +0.49 (+0.92%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$52.11 -1.44 (-2.69%) As of 05/21/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
